Bioton S.A. (BIO) - Total Liabilities
Based on the latest financial reports, Bioton S.A. (BIO) has total liabilities worth zł170.59 Million PLN (≈ $46.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Bioton S.A. to track the company's year-over-year net asset growth rate.
Bioton S.A. - Total Liabilities Trend (2005–2025)
This chart illustrates how Bioton S.A.'s total liabilities have evolved over time, based on quarterly financial data. See BIO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Bioton S.A. Competitors by Total Liabilities
The table below lists competitors of Bioton S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
USA | $9.74 Million |
|
DHI Group Inc
NYSE:DHX
|
USA | $95.20 Million |
|
Edel SE & Co. KGaA
F:EDL
|
Germany | €162.51 Million |
|
Mercan Kimya Sanayi ve Ticaret AS
IS:MERCN
|
Turkey | TL1.44 Billion |
|
CeoTronics AG
F:CEK
|
Germany | €14.01 Million |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
Turkey | TL2.39 Billion |
|
PT Mulia Industrindo Tbk
JK:MLIA
|
Indonesia | Rp2.01 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Bioton S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bioton S.A. (BIO) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioton S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioton S.A. (2005–2025)
The table below shows the annual total liabilities of Bioton S.A. from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł170.59 Million ≈ $46.95 Million |
-16.21% |
| 2024-12-31 | zł203.59 Million ≈ $56.03 Million |
-5.69% |
| 2023-12-31 | zł215.87 Million ≈ $59.41 Million |
+5.68% |
| 2022-12-31 | zł204.27 Million ≈ $56.22 Million |
-15.75% |
| 2021-12-31 | zł242.45 Million ≈ $66.73 Million |
-2.03% |
| 2020-12-31 | zł247.46 Million ≈ $68.11 Million |
-17.35% |
| 2019-12-31 | zł299.42 Million ≈ $82.40 Million |
+0.74% |
| 2018-12-31 | zł297.23 Million ≈ $81.80 Million |
-19.39% |
| 2017-12-31 | zł368.72 Million ≈ $101.48 Million |
-23.40% |
| 2016-12-31 | zł481.36 Million ≈ $132.48 Million |
+8.56% |
| 2015-12-31 | zł443.41 Million ≈ $122.03 Million |
-12.77% |
| 2014-12-31 | zł508.32 Million ≈ $139.90 Million |
+0.52% |
| 2013-12-31 | zł505.69 Million ≈ $139.17 Million |
-12.62% |
| 2012-12-31 | zł578.69 Million ≈ $159.26 Million |
-9.53% |
| 2011-12-31 | zł639.67 Million ≈ $176.05 Million |
+55.34% |
| 2010-12-31 | zł411.78 Million ≈ $113.33 Million |
-21.54% |
| 2009-12-31 | zł524.85 Million ≈ $144.45 Million |
-36.54% |
| 2008-12-31 | zł827.09 Million ≈ $227.63 Million |
+25.44% |
| 2007-12-31 | zł659.36 Million ≈ $181.47 Million |
+259.27% |
| 2006-12-31 | zł183.53 Million ≈ $50.51 Million |
+78.69% |
| 2005-12-31 | zł102.70 Million ≈ $28.27 Million |
-- |
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more